Bristol Myers’ Caforio stepping down as CEO in November

Commercial chief Christopher Boerner will take over after spending the next six months as chief operating officer. Giovanni Caforio will continue to serve as chair of Bristol Myers’ board.

By Jonathan Gardner • Updated April 26, 2023

Roche’s new eye drug pressures Eylea with strong launch

One year after its market debut, the company’s AMD drug Vabysmo is on track for blockbuster sales as Regeneron’s rival treatment faces new threats.

By Jonathan Gardner • April 26, 2023

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Bristol Myers boosts cell therapy production with Novartis plant

Accessing the Illinois facility will expand Bristol Myers’ supply of viral vectors following manufacturing struggles with CAR-T drugs Abecma and Breyanzi.

By Kristin Jensen • April 26, 2023

Novartis trims 10% of drug pipeline in research cutback

The company cut about 20 early-stage projects, including nine solid tumor programs, after reviewing their strategic fit and commercial potential.

By Christopher Newman • April 25, 2023

J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market

The planned IPO by the pharma’s consumer arm would value the new standalone company at over $40 billion.

By Ned Pagliarulo • April 25, 2023

Lilly sells emergency diabetes drug for $500M

The divestment of Baqsimi to Amphastar could net Lilly more than $1 billion if sales goals are met.

By Jonathan Gardner • April 24, 2023

Novartis plant cleared to produce in-demand cancer drug

The FDA has approved the pharma, which has had difficulty producing radiopharmaceutical drugs, to make its treatment Pluvicto at a New Jersey site.

By Delilah Alvarado • April 24, 2023

Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs

A second-generation treatment called eplontersen halted nerve damage and improved quality of life in a late-stage study the companies are using to seek U.S. approval.

By Ned Pagliarulo • April 24, 2023

Partnership is key to caring for multiple sclerosis patients throughout their journey

Empowering people to live healthier goes beyond developing the right treatments.

By Anne Berger, Head of Alliance Development, Viatris • April 24, 2023

The rise of AI in pharma: make it work for you

 AI-derived data can range from insightful to useless. Learn how to get one and not the other.

April 24, 2023

FDA approves earlier use of Roche’s Polivy in common form of lymphoma

The agency’s decision also converts the biologic drug's approval from accelerated to full, confirming an earlier OK based on tumor responses.

By Jonathan Gardner • April 20, 2023

Appeals court sides with Amgen in patent fight over psoriasis drug Otezla

With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.

By Kristin Jensen • April 20, 2023

J&J leans on cancer drug sales to maintain first quarter growth

Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

By Christopher Newman • April 18, 2023

GSK to buy Bellus Health and its chronic cough drug for $2B

The acquisition gives GSK a competitor to a similar drug being developed by Merck for the condition, which the companies estimate affects millions of people in the U.S.

By Ned Pagliarulo • April 18, 2023

Vaxcyte strengthens case for experimental pneumococcal vaccine

The company reported positive results from a second Phase 2 study of a shot that’s meant to challenge vaccines from Pfizer, Merck and GSK.

By Delilah Alvarado • Updated May 3, 2023

Navigate the complexities of cell and gene therapies

See how the effective use of CMC expertise helped guide a biopharma company’s development of a CGT product.

April 17, 2023

FDA again knocks back Alvotech’s Humira biosimilar

The agency rejected the partners’ copycat version of AbbVie’s blockbuster drug for a second time, citing problems spotted during the inspection of a manufacturing facility.

By Jonathan Gardner • April 14, 2023

Novo boosts sales outlook on strong demand for obesity drug

The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs. 

By Kristin Jensen • April 13, 2023

FDA, citing safety concerns, places partial hold on Merck KGaA’s MS drug

Evidence of possible liver damage among study participants adds to growing concerns about the potential of BTK inhibitors to treat MS, a strategy being pursued by several large drugmakers. 

By Kristin Jensen • April 12, 2023

AbbVie removes two approvals for blood cancer drug Imbruvica

In paring back use of Imbruvica, the drugmaker has become the latest developer to voluntarily withdraw indications for a cancer medicine following a setback in confirmatory testing.

By Delilah Alvarado • April 7, 2023

In NEJM, full Pfizer data show RSV vaccine’s protection

Shots from Pfizer and GSK could soon become the first approved for the common respiratory infection. Results published in the high-profile medical journal give a closer look at the former.

By Delilah Alvarado • Updated April 6, 2023

Pharma partner Sartorius eyes gene therapy market with $2.6B deal

The biotech tools supplier is acquiring Polyplus, a French company that makes components essential to the viral vector backbones of gene therapies.

By Ned Pagliarulo • March 31, 2023

Acquired patents aid J&J defense of top-selling drug from biosimilar challenge

The company is asserting patents gained via its 2020 acquisition of Momenta in litigation to forestall entry of a biosimilar to its psoriasis drug Stelara.

By Jonathan Gardner • March 29, 2023

Novartis, following Lilly, claims success in early breast cancer study

The Swiss drugmaker believes the findings could support an approval of Kisqali in adjuvant breast cancer and, potentially, broader use than Lilly’s rival drug Verzenio.  

By Jonathan Gardner • March 27, 2023

Pfizer returns cancer immunotherapy rights to Merck KGaA

Analysts had speculated Pfizer might divest its Bavencio interest to help close its Seagen buyout. A Pfizer spokesperson said the move was “conceived independently” of any other deal, however.

By Ned Pagliarulo • March 27, 2023